Affordable Access

Access to the full text

Cytokines in the Treatment of Melanoma

Authors
  • Bentebibel, Salah-Eddine1
  • Diab, Adi1
  • 1 The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA , Houston (United States)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
May 18, 2021
Volume
23
Issue
7
Identifiers
DOI: 10.1007/s11912-021-01064-4
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of ReviewThe use of cytokines in harnessing the immune system to eradicate cancer has been an important treatment modality. However, the dose-limiting toxicities of these cytokines limited their usage in clinic. Here, we review the basic biology of cytokines involved in the treatment of melanoma and discuss their therapeutic applications. Moreover, we describe several innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacy of these cytokines.Recent FindingsThe safety and the anti-tumor activity of newly engineered cytokines including PEGylated IL-2 (NKTR-214), PEGylated IL-10 (AM0010), and IL-15 super agonist (ALT-803) have been evaluated in clinical trials with encouraging clinical activity and acceptable safety profile, both as single agents and in combination with immuno-oncology agents.SummaryA greater understanding of the mechanisms of action and effective dosing of these newly engineered cytokine together with determination of optimum combination therapy regimens may yield greater clinical benefits in the future.

Report this publication

Statistics

Seen <100 times